The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed an unprecedented burden on individuals and societies worldwide. Despite global efforts, including lockdowns and public health interventions, the virus led to over a hundred million infections and millions of deaths. The development and deployment of vaccines have proven to be the most effective preventive measure against the virus; however, several critical public health questions remained unanswered. These included uncertainties regarding the long-term immune response, safety, and efficacy of COVID-19 vaccines, particularly in vulnerable populations and against emerging SARS-CoV-2 variants.
Although numerous clinical trials demonstrated vaccine safety and efficacy, Europe has played a limited role in these studies, making it less attractive for vaccine developers. The European vaccine development landscape has been fragmented, challenging to access, and lacking a strategic forum to address urgent vaccination-related questions. As a result, there has been a pressing need to establish a cohesive European approach to guide clinical vaccine trials and enhance pandemic preparedness.
To address these challenges, the VACCELERATE project was established as a pan-European clinical research network aimed at accelerating phase 2 and 3 vaccine development and strengthening Europe’s preparedness for future pandemics. Funded by the European Union under the Horizon 2020 program, VACCELERATE sought to streamline and harmonise clinical trial efforts across Europe, facilitating rapid access to trial sites, expert teams, and standardised protocols.
The primary objectives of VACCELERATE included building a clinical trial network, expediting vaccine research, engaging the public, harmonising data collection, capacity building, and including underrepresented populations, such as children and the elderly, in vaccine research.
Since its inception, VACCELERATE has successfully developed a robust, pan-European vaccine trial network, bridging gaps in clinical research and providing an essential platform for future pandemic preparedness. The network has improved accessibility to clinical trials, facilitated cross-border collaborations, and established best practices for data harmonisation and regulatory alignment.
Although EU funding for VACCELERATE ended on 27 Jan 2025, the established infrastructure and partnerships are expected to continue supporting vaccine research and public health initiatives. The project’s outcomes have laid the groundwork for a more coordinated and resilient European response to emerging infectious diseases, ensuring that Europe is better prepared for future public health challenges.
